$Eli Lilly(LLY.US) +5% premarket after the drugmaker posted 2Q sales ahead of expectations on the strength of its obesity drugs and raised FY’26 revenue full-year forecast above expectations. Foundayo revs (weight loss pill) launched in June beat expectations.
FY’2026 guidance: - Sees Revs $85.0B to $87.0B, saw $82.0B to $85.0B, vs $85.31B est. - Sees Adj EPS $35.50 to $36.50, saw $35.50 to $37 vs $33.56 est.2Q results:- Adj EPS $8.38 +32% Y/Y vs. $6.37 est- Revs $22.97 billion, +48% y/y, vs $20.59 estimate - Mounjaro revenue $9.94B vs $8.83B est- Zepbound revenue $4.93B vs $4.64B - Foundayo revenue $98M vs $92M est- Trulicity revenue $1.22B vs $869M est- Verzenio rev. $1.47B, -1% y/y, vs $1.5B est- Taltz rev. $856M vs $854.7M est- R&D expenses $3.82B vs $4.05B estThe copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments